



**EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE MEETING HELD ON WEDNESDAY 15th MARCH 2017 AT
12.30pm**

**IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Dr L Rogan (LR)	Head of Medicines Commissioning NHS EL CCG (Acting Chairperson)
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr T McKenzie (TM)	GP, EL CCG

In Attendance

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

2017/035: APOLOGIES:

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chairperson)
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Dr S Davies (SD)	GP, EL CCG
Mrs L Holden (LH)	Pharmacist LCFT (representing Ms S Ramdour)
Dr S Preeti (SP)	GP, BwD CCG

2017/036: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2017/037: MINUTES OF FEBRUARY MEETING:

Accepted as a correct record.

2017/038: MATTERS ARISING:

2016/155: Formulary Updates – Demeclocycline: - on main agenda

2017/007: Formulary Updates – Sodium valproate – information from LCFT on referral of women of childbearing age on sodium valproate back to mental health services presented. Concerns were expressed that re-referral did not include all patients of childbearing age. It was agreed that LH would follow up with LCFT to consider if all previous mental health service patients of childbearing age on sodium valproate should be referred back to mental health services for review. CD has had no progress with neurology for their review plans for patients in their service. NF to contact Gareth Price, Director of pharmacy LCFT to try to progress. Defer to next meeting.

2017/020: LMMG Recommendations (from Jan) Vitamin D Position Statement – comments fed back to LMMG. The issues raised will be included in an updated position statement.

2017/026: ELHT Antimicrobial Formulary – oral candidiasis updated – fluconazole now included in primary care guidelines as first line.

2017/039: NEW PRODUCT REQUEST - FERINJECT®

Ferinject® is requested by Obstetrics & Gynaecology as an alternative to Cosmofer® for antenatal ladies requiring IV iron, to reduce the admission time to administer the infusion. It will allow an increase in capacity and will release antenatal beds with patients able to be treated on the day unit.

Ferinject® was discussed in relation to shorter infusion time, reduced adverse effects, cost and staff time and it was agreed that it would be included on formulary as an option for any patient when IV iron is required. The directorate/ prescriber should consider overall cost effectiveness in their decision to use.

Resolved: Ferinject® to be included on formulary as an option when IV iron is required.

2017/040: NEW PRODUCT PROTOCOL - CABOZANTINIB

Cabozantinib is requested by Dr Charnley/Dr Parikh, Oncologists, as second line for metastatic renal cancer. It is licensed but there is currently no NICE or NHSE guidance and the company will provide free of charge. It was agreed that it could be used as long as care was managed by the trust. Note: to check if NICE TAG 432 Everolimus (see 2017/053) has been considered for these patients.

Resolved: Cabozantinib to be approved for use by oncologist after review and discussion of NICE TAG 432.

2017/041: NHSE COMMISSIONED – TOLVAPTAN FOR SIADH IN PATIENTS REQUIRING CANCER CHEMOTHERAPY

Tolvaptan is now commissioned by NHSE for SIADH in patients requiring cancer chemotherapy. It was approved for use in this condition in line with NHSE commissioning policy.

Tolvaptan for hyponatraemia was discussed based on limited evidence of efficacy and potential issues with safety. Demeclocycline for hyponatraemia also has limited evidence of efficacy. Both are considered in guidelines in European Journal of Endocrinology.

LR/JV to review existing guidelines and highlight issues at next meeting. AG to seek opinion of trust endocrinologists.

Resolved: Tolvaptan for SIADH in patient requiring cancer chemotherapy is approved in line with NHSE Policy.

Evidence and pathways for Tolvaptan & Demeclocycline for hyponatraemia to be reviewed.

2017/042: LMMG CONSULTATIONS (for Apr LMMG)

Empagliflozin Position Statement

The consultation was considered confusing by ELMMB. It does not help to clarify the position of empagliflozin within a treatment pathway and it is already included on formulary.

Pitolisant Recommendation

ELMMB supports the black recommendation.

Resolved: CW to send responses to LMMG.

2017/043: LMMG RECOMMENDATIONS (from February)

No completed recommendations.

2017/044: FORMULARY UPDATES

Alimemazine – Alternative (promethazine), more cost effective products have been identified and will be included on joint formulary. Alimemazine to be removed from formulary.

Alimemazine: Traffic Light: Black

Promethazine: Traffic Light: Green

Pregabalin - Axalid[®] – will be licensed for neuropathic pain from July 17. To be added as an option to formulary.

Traffic Light: Green

Galantamine Liquid – EL and BwD CCGs have been identified as outliers with high use of this liquid. ELMMB questioned the necessity of the product on formulary given availability of oro-dispersible tablets and patches of other products for the same indication. LR to refer to LCFT for advice on options for patients with swallowing difficulties currently taking galantamine MR capsules.

Unlicensed Specials – defer to next meeting.

Nefopam – the presented position statement was considered and it was approved. Nefopam to be given a black traffic light.

Traffic Light: Black

Resolved: Formulary to be updated as above.

2017/045: ELHT ANTIMICROBIAL FORMULARY – NEUTROPENIC SEPSIS UPDATE

Meropenem now added for penicillin allergy in discussion with oncologists. Approved for use.

Resolved: ELMMB approved.

2017/046: ELHT ANTIMICROBIAL FORMULARY – MENINGITIS UPDATE

Updated meningitis section in line with recent national guideline changes. Encephalitis box needs arrow correcting. Approved for use.

Resolved: ELMMB approved.

2017/047: ELHT PERI-PROCEDURAL MANAGEMENT OF PATIENTS ON ORAL ANTICOAGULANTS & ANTIPLATELETS

Guidance for peri-procedural management of patient on oral anticoagulants and anti-platelets has been produced in conjunction with haematologist. Comment – the reference to CHADS₂ should now be to CHADSVASc and a request for specific anti-platelets to be listed. Approved for use when amendments completed.

Resolved: ELMMB approved when amendments completed.

2017/048: CHEMOTHERAPY NETWORK GUIDELINE FOR USE OF ARANESP®

Approved for use in ELHE.

Resolved: ELMMB approved.

2017/049: PHARMACY PROCESS TO ASSESS MEDICINES SUPPORT NEEDS

This process has been developed for use by the medicines support team when assessing patient's requirements in community/domiciliary settings for support with medicines.

Resolved: ELMMB approved.

2017/050: PRESCRIBING FOR TRANSGENDER PATIENTS

Guidance has been adapted from Fylde & Wyre document. Accepted by ELMMB.

Resolved: ELMMB accepted the guidance.

2017/051: COVERT MEDICATION GUIDANCE FOR CARE HOMES

This guidance has been updated in line with legislation changes.

Resolved: ELMMB approved.

2017/052: LMMG DEVELOPMENT PROPOSALS

The proposals have been compiled by Lancashire North CCG on behalf of all the Lancashire CCGs. The proposals refer to a Lancashire decision making process and how this may be implemented going forwards across the Lancashire footprint. Please can members forward comments to LR to forward on to Lancashire Pharmacy CCG leads meeting via N. Lancs Lead.

Resolved: ELMMB acknowledged.

2017/053: NICE RECOMMENDATIONS (from Feb)

Everolimus for advanced renal cell carcinoma after previous treatment (TAG 432) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned.

Traffic Light: RED

Apremilast for treating active psoriatic arthritis (TAG 433) is recommended as an option by NICE. Approved in line with NICE. . CCG commissioned.

Traffic Light: RED

STANDING ITEMS

2017/054: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – February 2017

Minutes acknowledged

2017/055: FOR ACTION/INFORMATION: LANCASHIRE CARE FOUNDATION TRUST D&T MINUTES – January 2017

Minutes acknowledged

DATE OF NEXT MEETING – Next meeting is Wednesday 19th April 2017 12.30pm, Seminar Room 6, Learning and Development Centre, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 15TH MARCH 2017

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2017/007	Formulary Updates – Sodium valproate – ask LCFT to consider all patients to be referred back. Discuss with neurology	LH	Apr 17
		NF	Apr 17
2017/020	LMMG Recommendations (from Jan)- Vitamin D Position Statement Review local products	LR	Apr 17
2017/041	Tolvaptan/Demeclocycline for Hyponatraemia – European guidance to be reviewed	LR	Apr 17